$ABT

Generating a unique summary for ABT…

AI-generated for information only — not investment advice.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Institutions hold 81.87% · insiders 0.49% · 3,816 institutions

Consensus score 1.46 (1 = strong buy, 5 = sell) · mean target 118.52

• Wells FargoOverweightmain2026-10-23
• CitigroupBuymain2026-10-22
• RBC CapitalOutperformmain2026-10-22
• Wells FargoOverweightmain2026-10-22
• JP MorganOverweightmain2026-10-22
• TD CowenBuymain2026-10-22
• BairdOutperformmain2026-10-22
• BTIGBuymain2026-10-22
• TD CowenBuyreit2026-10-16
• BarclaysOverweightinit2026-10-07

Next report: 2026-10-21

• 8-KCorporate Changes & Voting Matters2026-10-21Open
• 8-KCorporate Changes & Voting Matters2026-08-20Open
• 10-QPeriodic Financial Reports2026-07-28Open
• 8-KCorporate Changes & Voting Matters2026-07-16Open
• 11-KAnnual report of employee stock purchase2026-06-18Open
• SDSpecialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)2026-05-27Open
• 10-QPeriodic Financial Reports2026-04-29Open
• 8-KCorporate Changes & Voting Matters2026-04-27Open
• S-8Offering Registrations2026-04-24Open
• 8-KCorporate Changes & Voting Matters2026-04-17Open

• Abbott Laboratories (ABT) Posted Higher Sensitivity Data For Colorectal Cancer Recurrence Detection

  Abbott Laboratories (NYSE:ABT) reported new Beta-CORRECT study data on its Oncodetect test at ESMO 2026. The Beta-CORRECT trial showed a significant sensitivity improvement for detecting colorectal cancer recurrence using circulating tumor DNA. The Oncodetect assay targets low levels of tumor DNA in the bloodstream to support closer monitoring of patients after colorectal surgery. The sensitivity gains for Oncodetect in the Beta-CORRECT study are important, but investors should weigh them...

  Sat, 24 Oct 2026 10:13:00 +0000

• Clinical Laboratory Molecular Diagnostics for Infectious Diseases Market, 2025-2029: Forecast by Application, Place, and Country | Multiplex and Rapid Testing Unlock Growth

  A 354-page report profiles 36 companies, including Abbott, bioMérieux, Roche and Thermo Fisher, across respiratory, gastrointestinal and meningitis testing in 15 countries — though costs and shifting disease prevalence complicate the outlookDublin, Oct. 23, 2026 (GLOBE NEWSWIRE) -- "Clinical Laboratory Molecular Diagnostics for Infectious Disease Markets 2025-2029: Strategies, Trends, and Forecasts by Application, Place and Country with Market Analysis & Executive Guides" has been added to Resea

  Fri, 23 Oct 2026 14:07:00 +0000

• Pacemakers Market Forecasts Growth from $5.4 Billion (2025) to $7.5 Billion by 2030, Profiling Medtronic, Abbott, Boston Scientific, Biotronik & 6 Other Key Players

  108-Page Report Examines the Shift to Leadless and MRI-Compatible Devices as Rising Arrhythmia Prevalence Drives Demand, While High Procedure Costs, Strict Approvals and Cybersecurity Risks Weigh on GrowthDublin, Oct. 23, 2026 (GLOBE NEWSWIRE) -- "Pacemakers: Global Markets" has been added to ResearchAndMarkets.com's offering. The report delivers a comprehensive analysis of the global pacemakers market, covering revenue performance, growth prospects, technology developments, regulatory condition

  Fri, 23 Oct 2026 14:02:00 +0000

• Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer

  For patients with colorectal cancer, surgery can remove visible cancer, but it can be difficult to know whether minute traces of the disease remain. Abbott (NYSE: ABT) today announced new Beta-CORRECT data presented at the European Society for Medical Oncology (ESMO) Congress showing that the whole-genome sequencing (WGS)-based Oncodetect® molecular residual disease (MRD) test achieved a 30-percent absolute improvement in sensitivity for colorectal cancer recurrence within two years of surgery,

  Fri, 23 Oct 2026 13:15:00 +0000

• Is Abbott Stock About To Rebound?

  For questions about this article or underlying research, email help@trefis.com.

  Fri, 23 Oct 2026 13:12:30 +0000

• Catheter Precision Announces Publication of Comparative Study Showing LockeT Outperforms Abbott’s Perclose Internal Vascular Closure Device

  FORT MILL, S.C, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, a wholly owned subsidiary of Flyte Aviation, Inc. (NYSE American: VJET), today announced the first published comparative study evaluating its LockeT suture retention device against a traditional internal vascular closure device (VCD) following large bore venous access. The 172-patient peer-reviewed study, titled "Vascular closure with a suture retention device versus suture-mediated closure system after large bore venous acces

  Thu, 22 Oct 2026 20:54:00 +0000

• Abbott Laboratories' 2026 Guidance Cut Driven by Diabetes, Electrophysiology Portfolio, RBC Says

  Abbott Laboratories' (ABT) 2026 guidance cuts were driven by headwinds related to its diabetes and e

  Thu, 22 Oct 2026 15:07:47 +0000

• Australia Bionic Devices Market Size, Share, Growth, and Forecast 2026-2034 Featuring Profiles of Cochlear, Medtronic Australasia, Edwards Lifesciences Australia, Baxter Int'l, Boston Scientific Corp., Abiomed Australia, Abbott Labs

  Dublin, Oct. 22, 2026 (GLOBE NEWSWIRE) -- "Australia Bionic Devices Market Report by Product, Fixation, Technology, End User, States and Companies Analysis 2026-2034" has been added to ResearchAndMarkets.com's offering. According to the report, the market is expected to increase from US$ 117.32 Million in 2025 to US$ 248.98 Million in 2034, registering a CAGR of 8.72% during 2026-2034. Growth is being driven by the expanding use of cochlear implants, advanced prosthetics, neurostimulation system

  Thu, 22 Oct 2026 14:35:00 +0000